Key Points
- VP Daniel Lippis sold 1,019 shares on May 1 at an average price of $83.01 for $84,587.19 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 2.92% to 33,934 shares valued at about $2.82M.
- Edwards beat Q1 expectations with $0.78 EPS vs. $0.73 and $1.65B revenue (up 16.7% y/y) and issued FY2026 guidance of $2.95–3.05 EPS and Q2 guidance of $0.70–0.76 EPS.
- Analysts carry a consensus "Moderate Buy" with a $95.65 target; the stock has a ~$48B market cap, trades in a 52‑week range of $72.30–$87.89, and is ~79% institutionally owned.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the firm's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Down 0.8%
Shares of NYSE EW opened at $83.32 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $87.89. The stock has a market capitalization of $48.04 billion, a P/E ratio of 44.32, a PEG ratio of 2.11 and a beta of 0.87. The stock's fifty day moving average is $82.08 and its 200 day moving average is $82.54.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. During the same quarter in the previous year, the business posted $0.64 earnings per share. The business's revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on EW. TD Cowen upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Friday, January 9th. Wolfe Research upgraded Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Piper Sandler reiterated an "overweight" rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Robert W. Baird lifted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research report on Friday, April 24th. Finally, Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a "hold" rating in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $95.65.
Check Out Our Latest Research Report on EW
Hedge Funds Weigh In On Edwards Lifesciences
A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Norges Bank acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the period. Viking Global Investors LP acquired a new position in shares of Edwards Lifesciences in the third quarter worth approximately $238,688,000. Marshall Wace LLP lifted its stake in shares of Edwards Lifesciences by 66.1% in the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company's stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
